ShareSoc & Walbrook PR Healthcare Companies Hybrid Event, London – 19 October 2023, 5pm
Join us on 19th of October for our first hybrid event in London. This event will consist of an in-person seminar in London, which will also be streamed live (and recorded), allowing members to watch virtually.
Please register to attend the event in-person or to watch virtually, using the 2 different links below.
Each of the 5 companies will present for 15 minutes and then take your questions for another 15 minutes. All attendees (whether attending in-person or virtually) will be able to ask questions and those attending the seminar will be able to network with company directors and fellow investors over drinks and a buffet.
Event registration opens at 4.30 pm and presentations commence at 5.00 pm.
Networking will be from 8:00pm to 9:00pm.
Tristel Plc (TSTL) is a UK-based manufacturer of infection prevention products. The Company’s core business is the sale to hospitals of its Chlorine Dioxide chemistry used for the decontamination of medical devices under the Tristel brand, and for the sporicidal disinfection of environmental surfaces under the Cache brand. Tristel’s powerful and fast acting disinfectant uses a proprietary formulation of Chlorine Dioxide and is used in nearly every NHS hospital to decontaminate medical devices or as a surface disinfectant, as well as across 30 plus countries worldwide.
Inspiration Healthcare (AIM: IHC) is a global provider of medical technology for use in neonatal intensive care & operating theatres. The Company provides high-quality innovative products to patients around the world which help to improve patient outcomes and it actively invests in innovative product opportunities and disruptive technologies.
The Company has key own-brand products that can be used within the first days of life to help premature and sick babies; helping resuscitation and stabilisation in the first moments of life through to preventing brain damage and both invasive and non-invasive respiratory support in terms of capital equipment and disposable medical devices. Additionally, the Company has its own range of products for maintaining normothermia pre, during and post-surgery.
Creo Medical Group (CREO) is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.
The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency (“RF”) energy for precise localised cutting and focused high-frequency microwave (“MW”) energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group’s range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company’s technology can impact the landscape of surgery and endoscopy by providing a safer, less invasive and more cost-efficient option for procedures.
Abingdon Health (ABDX) is a leading lateral flow contract development and manufacturing organisation (“CDMO”) offering its services to an international customer base across industry sectors that include clinical, animal health, plant health, and environmental testing.
The Company’s CDMO division offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in, allowing for rapid decision making, targeted intervention and supporting better outcomes.
GENincode (GENI) is a UK-based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.
GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode’s CE marked in vitro diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict the onset of cardiovascular disease.